Nocardia veterana infections: case report and systematic review

C. Radcliffe¹, D. Peaper¹,² and M. Grant¹,³

¹) Yale School of Medicine, New Haven, CT, USA, ²) Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT, USA and ³) Department of Internal Medicine, Section of Infectious Diseases, Yale New Haven Hospital, New Haven, CT, USA

Abstract

Members of the genus Nocardia are filamentous, Gram-positive, aerobic bacteria and exist ubiquitously in most environments. In 2001, the species Nocardia veterana was first isolated, and it predominantly causes pulmonary infections in immunocompromised hosts. We present the first report of a soft-tissue abscess caused by N. veterana in a 59-year-old woman being treated for chronic cutaneous graft-versus-host disease. After failing to improve with empirical treatment, two incision and drainage procedures were required. She subsequently completed a 1-year course of oral antibiotic therapy consisting of trimethoprim-sulfamethoxazole then azithromycin. No relapse occurred over the next 5 years of follow up. To better characterize N. veterana infections, we performed a systematic literature review and summarized all previously reported cases. Overall, the rising prevalence of immunocompromising conditions warrants increased vigilance for infections caused by atypical or opportunistic pathogens.

Keywords: Abscess, graft-versus-host disease, Nocardia veterana, nocardiosis, trimethoprim-sulfamethoxazole

Original Submission: 15 June 2020; Revised Submission: 30 November 2020; Accepted: 1 December 2020
Article published online: 5 December 2020

Materials and methods

We present the first report of a soft-tissue abscess caused by N. veterana in a 59-year-old woman being treated for chronic cutaneous graft-versus-host disease (GVHD). Review of medical records was approved by our institution’s institutional review board. To better characterize N. veterana infections, we performed a systematic literature review and summarized all previously reported cases.

Case presentation

A 59-year-old woman with a history of acute lymphoblastic leukaemia—status post-haematopoietic stem cell transplantation—presented to the emergency department for evaluation of a right shoulder cutaneous abscess. Her post-transplant course had been complicated by multiple episodes of gastrointestinal and cutaneous GVHD. At this time, she was receiving phototherapy for chronic cutaneous GVHD and had...
started taking prednisone (30 mg daily) 6 months before presentation. Her medications included tacrolimus, acyclovir, fluconazole and monthly pentamidine. Two weeks before presentation, she had been evaluated by her oncologist for a 5 × 7 cm erythematous, indurated region on her right shoulder, and empiric treatment with oral minocycline (100 mg twice a day) was initiated. Continued pain prompted an outpatient ultrasound, which demonstrated a fluid collection. Her referring provider then sent her to the emergency department for further evaluation.

Incision and drainage were performed in the emergency department and yielded copious, purulent drainage that was sent for culture. Antibiotic therapy was empirically switched to oral clindamycin (600 mg three times a day). She was afebrile and discharged shortly thereafter. Two days later, she was admitted after a wound check showed increasing erythema around the incision and drainage site. Laboratory studies were notable for leucocytosis (15 200/μL; reference range 4000–10 000/μL), but she remained afebrile. Magnetic resonance imaging of her right upper extremity demonstrated a 2-cm soft-tissue abscess involving superficial fascia of the lateral deltoid and focal myositis (Fig. 1). Antibiotic therapy was broadened to intravenous vancomycin and piperacillin-tazobactam.

On day 2 of hospitalization, the abscess was incised and drained by general surgery. The following day, the culture from her initial presentation to the emergency department grew 4+ Gram-positive rods, prompting Nocardia spp. to be suspected. Antibiotic therapy was switched to oral trimethoprim-sulfamethoxazole (800 mg-160 mg twice a day). Magnetic resonance imaging of the brain and a CT scan of the chest showed no evidence of involvement, and she was discharged on day 4.

Four days after discharge, the isolate from her initial presentation was identified as N. veterana. The MicroSEQ® 500bp 16S rRNA Sequencing Kit (Applied Biosystems, Foster City, CA, USA) was used. Samples were processed and analysed consistent with the manufacturer’s instructions. Data were assembled with MicroSEQ software, and amplicons were compared against the MicroSEQ database. Clinical and Laboratory Standards Institute MM18 criteria were used for making an identification. The aligned sequence was 409 bp, with no mixed bases. The isolate was 100% match to N. veterana in the MicroSEQ database; however, the National Center for Biotechnology Information BLAST database has been updated since the time of the isolate’s processing, and a Nocardia elegans strain was retrospectively identified as a 100% match during the preparation of this report. Notably, three strains of N. veterana were 100% matches.

Susceptibility testing was sent out to the University of Texas Health Center’s Department of Microbiology Research in Tyler, Texas. The isolate’s susceptibility profile is summarized in Table 1. Two weeks later, the woman was seen as an outpatient and had been tolerating trimethoprim-sulfamethoxazole therapy. Seventy-three days after discharge, elevated creatinine (3.1 mg/dL, baseline 1.9 mg/dL; reference range 0.6–1.2 mg/dL) was attributed to the use of trimethoprim-sulfamethoxazole in combination with tacrolimus, and antibiotic therapy was switched to oral azithromycin (500 mg daily). This decision was informed by the isolate’s susceptibility profile and discussion with the reference laboratory.

Roughly 1.5 months later, her creatinine had returned to baseline (1.7 mg/dL), and she had been tolerating azithromycin without adverse events. In the absence of symptoms attributable to her N. veterana infection, azithromycin therapy was discontinued 289 days after its initiation. She continued to receive phototherapy for GVHD and remained on prednisone (20 mg daily), acyclovir, fluconazole and monthly pentamidine. She was seen 6 months after completing her 1-year course of therapy and displayed no signs of relapse. More than 5 years since completing therapy, no relapse has occurred.

**Literature review and discussion**

Our case concerned an N. veterana infection in a 59-year-old woman who had been receiving immunosuppressive therapy for chronic cutaneous GVHD. She failed to respond to empiric
minocycline, and an abscess was incised and drained twice before resolving. Fortunately, oral antibiotic therapy was capable of treating the infection then serving as prophylaxis against relapse. Acute kidney injury complicated her course, but azithromycin therapy ultimately proved tolerable and successful.

| TABLE 2. Nocardia veterana isolate susceptibility profilea |
|----------------------------------------------------------|
| Susceptible | Intermediate | Resistant | No standardized breakpoint for Nocardia spp. |
|--------------|--------------|-----------|--------------------------------------------|
| Amikacin (MIC ≤ 1 μg/mL) | Ceftriaxone (MIC 16 μg/mL) | Amoxicillin-clavulanate (MIC 32–16 μg/mL) | Ertapenem (MIC unavailable; susceptible by bacterial breakpoint) |
| Clarithromycin (MIC < 0.06 μg/mL) | Kanamycin (MIC unavailable) | Ciprofloxacin (MIC > 4 μg/mL) | Meropenem (MIC unavailable; susceptible by rapidly growing mycobacteria breakpoint) |
| Imipenem (MIC ≤ 2 μg/mL) | Linezolid (MIC 2 μg/mL) | Minocycline (MIC 2 μg/mL) | Tigecycline (MIC 4 μg/mL) |
| Trimethoprim-sulfamethoxazole (MIC 1–19 μg/mL) | | | |

aSusceptibility results are reported with reference to their MICs and respective, standardized breakpoints.

To better characterize N. veterana infections, we searched PubMed with the following operators: (‘Nocardia veterana’ OR ‘N. veterana’) AND (infection OR infections). Articles’ citation lists were also reviewed to identify cases. We excluded one abridged report of a mycetoma [10] whose full details were published in a later manuscript [11]. Table 2 summarizes our case and all reported cases of N. veterana infections.

| TABLE 2. Nocardia veterana infections |
|--------------------------------------|
| Age/sex | Clinical syndrome | Immunocompromising co-morbidities | Initial anti-nocardial regimen | Length of treatment | Outcome | Ref. |
|---------|-------------------|----------------------------------|-----------------------------|--------------------|---------|------|
| 83/F    | bowel abscess     | malignancy                       | TMP-SMX                    | >3 months          | success | [9]  |
| 73/M    | brain abscess     | diabetes mellitus                | meropenem                   | 1 year             | success | [9]  |
| 68/M    | endophthalmitis   | heart transplant, diabetes       | meropenem, linezolid         | planned length of 12 months | success | [9]  |
| 52/M    | pulmonary infection | chronic granulomatous disease  | amoxicillin                 | >6 years           | success | [11] |
| 72/M    | nodular lymphangitis | immunosuppressive therapy for interstitial pneumonitis | TMP-SMX                  | planned length of 3 months | stable at time of report | [13] |
| 40/M    | peritoneal infection | AIDS, chronic hepatitis B,       | died before treatment       | not applicable     | died before treatment | [14] |
|         |                   | malignancy                       | initiation                  |                     | initiation |       |
| 24/F    | pulmonary infection | chronic granulomatous disease   | amikacin, ceftriaxone, trimethoprim | >3 months          | stable at time of report | [15] |
| 40/F    | pulmonary infection | HIV                              | TMP-SMX                    | 6 months           | success | [16] |
| 43/F    | pulmonary infection | immunosuppressive therapy for SLE | TMP-SMX                  | 6 months           | success | [17] |
| 47/M    | pulmonary infection | liver transplant                 | not reported                | 397 days           | success | [19] |
| 52/M    | pulmonary infection | HSCT recipient treated for GVHD | not reported                | not reported       | not reported | [18] |
| 52/F    | pulmonary infection | HSCT recipient treated for GVHD  | TMP-SMX                    | 154 days           | success | [19] |
| 63/M    | pulmonary infection | lung transplant                  | TMP-SMX                    | 15 days            | success | [16] |
| 65/M    | pulmonary infection | lung transplant,               | imipenem                   | >6 months          | success | [16] |
|         |                   | immunosuppressive therapy for bronchiolitis obliterans | TMP-SMX                  | 16 weeks           | success | [15] |
| 67/F    | pulmonary infection | HSCT recipient treated for GVHD  | imipenem/clizastatin, amikacin | 722 days          | died from encephalitis of unknown aetiology | [6] |
| 78/M    | pulmonary infection | recurrent pneumonias and bronchiectasis | minocycline          | >7 weeks           | symptomatic improvement at time of report | [17] |
| 58/M    | pulmonary infection | history of tuberculosis         | not reported                | not reported       | not reported | [4]  |
|         |                   | lung transplant                 | TMP-SMX                    | 30 days            | success | [7]  |
| 58/F    | pulmonary infection | malignancy, recent prednisone course for autoimmune haemolytic anaemia | TMP-SMX, azithromycin, piperacillin-tazobactam | 3 weeks            | success | [20] |
| 30/M    | pulmonary infection with bacteremia | HIV, chronic hepatitis B, history of tuberculosis | TMP-SMX | <1 month | died from multi-organ failure | [5] |
| 51/M    | pulmonary infection with bacteremia | malignancy, peritoneal dialysis | TMP-SMX | <2 months | died from underlying malignancy | [21] |
| 59/F    | soft-tissue abscess | HSCT recipient treated for GVHD | TMP-SMX | 1 year | success | our case |

Abbreviations: AIDS, acquired immunodeficiency syndrome; GVHD, graft-versus-host disease; HIV, human immunodeficiency virus; HSCT, haematopoietic stem cell transplantation; SLE, systemic lupus erythematosus; TMP-SMX, trimethoprim-sulfamethoxazole.
Mean age was 55 years, and 29% were women. Pulmonary infections accounted for 17 of 24 infections, with abscesses being the second most common (3 of 24). In total, 25% had previous solid organ transplantations, 17% of patients had undergone haematopoietic stem cell transplantation and were undergoing treatment for GVHD, and 13% were people living with human immunodeficiency virus. The duration of treatment ranged from 3 weeks to >6 years. Trimethoprim-sulfamethoxazole monotherapy was used as initial antinocardial therapy for 13 of 24 individuals and led to treatment success in 9 of 13 (69%) of them. Combination therapy or other monotherapy (e.g. amoxicillin) was successful for six of eight (75%) individuals. The number of patients was too small to determine whether the difference in outcome is statistically significant.

Overall, N. veterana has a predilection for causing pulmonary infections in individuals with immunocompromising conditions [4–7,15–20], and trimethoprim-sulfamethoxazole is commonly used to treat infections caused by Nocardia spp. [1]. When planning management for an immunocompromised host, a prolonged treatment duration is recommended. For our patient, the concurrent use of immunosuppressive therapy to manage GVHD heightened her susceptibility to N. veterana infection, and disseminated disease was fortunately averted by extended antibiotic therapy. The rising prevalence of immunocompromising conditions warrants increased vigilance for infections caused by atypical or opportunistic pathogens.

Conflict of interest

The authors declare no conflicts of interest.

References

[1] Wilson JW. Nocardiosis: updates and clinical overview. Mayo Clin Proc 2012;87:403–7.
[2] Brown-Elliott BA, Brown JM, Convil PS, Wallace Jr RJ. Clinical and laboratory features of the Nocardia spp. based on current molecular taxonomy. Clin Microbiol Rev 2006;19:259–82.
[3] Beamam BL, Burnside J, Edwards B, Causey W. Nocardial infections in the United States, 1972–1974. J Infect Dis 1976;134:286–9.
[4] Gurtler V, Smith R, Mayall BC, Potter-Reinemann G, Stackebrandt E, Kroppenstedt RM. Nocardia veterana sp. nov., isolated from human bronchial lavage. Int J Syst Evol Microbiol 2001;51:933–6.
[5] Liu WL, Lai CC, Hsiao CH, Hung CC, Huang YT, Liao CH, et al. Bacteremic pneumonia caused by Nocardia veterana in an HIV-infected patient. Int J Infect Dis 2011;15:e430–2.
[6] Kurosawa S, Sekiya N, Doki N, Yaguchi T, Kishida Y, Nagata A, et al. The emergence of rare nocardiosis following allogeneic hematopoietic stem cell transplantation in the era of molecular taxonomy. Int J Infect Dis 2019;89:154–62.
[7] Agterof MJ, van der Bruggen T, Tersmette M, ter Borg Ej, van den Bosch JM, Biesma DH. Nocardiosis: a case series and a mini review of clinical and microbiological features. Neth J Med 2007;65:199–202.
[8] Schiebusch S, Nimmo G, Carter R. Bowel abscess with Nocardia veterana associated with colon carcinoma. Pathology 2010;42:306–7.
[9] Arends JE, Stemerding AM, Vorst SP, de Neeling AJ, Weersink AJ. First report of a brain abscess caused by Nocardia veterana. J Clin Microbiol 2011;49:4364–5.
[10] Kano R, Hattori Y, Murakami N, Mine N, Kashima M, Kroppenstedt RM, et al. The first isolation of Nocardia veterana from a human mycetoma. Microbiol Immunol 2002:46:409–12.
[11] Kashima M, Kano R, Mikami Y, Takahama H, Ito M, Hasegawa A, et al. A successfully treated case of mycetoma due to Nocardia veterana. Br J Dermatol 2005;152:1349–52.
[12] Scott M, Mehta S, Rahman HT, Grossniklaus HE, Yeh S. Nocardia veterana endogenous endophthalmitis in a cardiac transplant patient. J Ophthalmic Inflamm Infect 2013;3:44.
[13] Dua J, Clayton R. First case report of Nocardia veterana causing nodular lymphangitis in an immunocompromised host. Australas J Dermatol 2014;55:e48–50.
[14] Godreuil S, Didelot MN, Perez C, Lefebre A, Boiron P, Reyes J, et al. Nocardia veterana isolated from ascitic fluid of a patient with human immunodeficiency virus infection. J Clin Microbiol 2003;41:2768–73.
[15] Convil PS, Brown JM, Steigerwalt AG, Lee JW, Byrer DE, Anderson VL, et al. Nocardia veterana as a pathogen in North American patients. J Clin Microbiol 2003;41:2560–8.
[16] Minero MV, Marin M, Cercenado E, Rabadán PM, Bouza E, Munoz P. Nocardiosis at the turn of the century. Medicine (Balt) 2009;88:250–61.
[17] Pottumarthy S, Limaye AP, Prentice JL, Houze YB, Swanzy SR, Baker T, et al. Expanded spectrum of Nocardia species causing clinical nocardiosis detected by molecular methods. Int J Med Microbiol 2002;292:277–82.
[18] Molina A, Winston DJ, Pan D, Schiller GJ. Increased incidence of nocardial infections in an era of atovaquone prophylaxis in allogeneic hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2018;24:1715–20.
[19] Ansari SR, Saffar A, Han XY, O’Brien S. Nocardia veterana bloodstream infection in a patient with cancer and a summary of reported cases. Int J Infect Dis 2006;10:483–6.
[20] Poinsel E, Roseau JB, Landais C, Rodriguez-Nava V, Bussy E, Gailllard T. Nocardia veterana: disseminated infection with urinary tract infection. Braz J Infect Dis 2015;19:216–9.